Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates
Jorge Mestre-Ferrandiz (),
Adam Parnaby and
Additional contact information
Jaime Espin: Andalusian School of Public Health
Michael Schlander: University of Heidelberg
Brian Godman: Karolinska Institutet
Pippa Anderson: Swansea University
Jorge Mestre-Ferrandiz: Independent Economics Consultant
Isabelle Borget: Gustave Roussy, Service de Biostatistique et d’Epidémiologie
Adam Hutchings: Dolon Ltd
Steven Flostrand: Celgene International
Adam Parnaby: Celgene International
Claudio Jommi: Università del Piemonte Orientale
Applied Health Economics and Health Policy, 2018, vol. 16, issue 6, 803-817
Abstract Background Within (European) healthcare systems, the predominant goal for pharmaceutical expenditure is cost containment. This is due to a general belief among healthcare policy makers that pharmaceutical expenditure—driven by high prices—will be unsustainable unless further reforms are enacted. Objective The aim of this paper is to provide more realistic expectations of pharmaceutical expenditure for all key stakeholder groups by estimating pharmaceutical expenditure at ‘net’ prices. We also aim to estimate any gaps developing between list and net pharmaceutical expenditure for the EU5 countries (i.e. France, Germany, Italy, Spain, and the UK). Methods We adjusted an established forecast of pharmaceutical expenditure for the EU5 countries, from 2017 to 2021, by reflecting discounts and rebates not previously considered, i.e. we moved from ‘list’ to ‘net’ prices, as far as data were available. Results We found an increasing divergence between expenditure measured at list and net prices. When the forecasts for the five countries were aggregated, the EU5 (unweighted) average historical growth (2010–2016) rate fell from 3.4% compound annual growth rate at list to 2.5% at net. For the forecast, the net growth rate was estimated at 1.5 versus 2.9% at list. Conclusions Our results suggest that future growth in pharmaceutical expenditure in Europe is likely to be (1) lower than previously understood from forecasts based on list prices and (2) below predicted healthcare expenditure growth in Europe and in line with long-term economic growth rates. For policy makers concerned about the sustainability of pharmaceutical expenditure, this study may provide some comfort, in that the perceived problem is not as large as expected.
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
http://link.springer.com/10.1007/s40258-018-0419-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:16:y:2018:i:6:d:10.1007_s40258-018-0419-1
Ordering information: This journal article can be ordered from
Access Statistics for this article
Applied Health Economics and Health Policy is currently edited by Timothy Wrightson
More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla ().